Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Conditions:   Nasopharyngeal Carcinoma;   EBV-Related Gastric Carcinoma;   EBV-Related Leiomyosarcoma;   EBV Related Carcinoma;   EBV-Related Sarcoma Interventions:   Drug: Nanatinostat;   Drug: Pembrolizumab;   Drug: Valganciclovir Sponsor:   Viracta Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials